G-Med

As #BreastCancerAwarenessMonth comes to a close, we want to extend a heartfelt thank you to our engaged G-Med physician community. Your dedication to discussing, sharing, and advancing knowledge around breast cancer and its treatment options has been truly inspiring. Throughout October, we’ve seen remarkable activity from our global network of doctors, highlighting the commitment to improve care for those impacted by breast cancer. From discussions on early detection strategies to insights on the latest treatment innovations, your contributions help shape a more informed and proactive medical community. Let’s carry this momentum forward, ensuring that breast cancer awareness and advocacy extend well beyond this month. #BreastCancerAwareness #HealthcareInnovation #CancerCare #BreastCancerTreatment Eli Lilly and Company ANI Pharmaceuticals, Inc. Novartis Pfizer

What Content Do HCPs Really Want from #Pharma? HCPs today expect more than product info—they want content that truly supports patient care, is trustworthy, and fits their busy schedules. G-Med's latest blog breaks down what HCPs value most: 👉 #Patient-Centric #Insights 👉Trusted, Evidence-Based Resources 👉Quick, Accessible Formats 👉On-Demand Digital Access Ready to elevate your #HCP engagement strategy? Read the full blog to learn more! Link in comments 👇

New Insights on Thyroid Cancer from G-Med 📊 Explore the latest global discussions from 111,000+ physicians on thyroid cancer diagnosis, treatment, and follow-up care. Discover key trends, geographical differences, and the challenges faced by #HCPs in managing this disease. This report offers #actionable #insights to enhance your healthcare marketing strategies by aligning with real-time physician concerns. Link to full report in comments 👇 Sanofi Exelixis Novartis Rigel Pharmaceuticals Inc.

New Insights on Thyroid Cancer from G-Med 📊 Explore the latest global discussions from 111,000+ physicians on thyroid cancer diagnosis, treatment, and follow-up care. Discover key trends, geographical differences, and the challenges faced by #HCPs in managing this disease. This report offers #actionable #insights to enhance your healthcare marketing strategies by aligning with real-time physician concerns. Link to full report in comments 👇 Sanofi Exelixis Novartis Rigel Pharmaceuticals Inc.

Sustainability in Healthcare is a Necessity, Not an Option 🌍 At G-Med, we're proud to announce our updated ESG policy, focusing on waste reduction, resource conservation, and diversity and inclusion. Join us in driving positive environmental change in healthcare! Read our full press release for more details. 👇 #Sustainability #HealthcareInnovation #ESG #DiversityAndInclusion #HealthcareTransformation #GreenHealthcare

Did you know that nearly 90% of #HCP's believe the #pharmaceutical industry is underutilizing social media? With the rise of online #healthcare conversations, there's a golden opportunity for #pharma to engage more effectively with both providers and patients. Check out G-Med's latest blog post to explore how embracing social media #marketing can maximize impact and foster deeper connections in the digital healthcare landscape! Link in comments 👇

G-Med is committed to a more sustainable future! We've updated our #ESG policy to focus on waste reduction, resource conservation, and diversity. Additionally, our latest white paper analysing peer-to-peer discussions on G-Med offers insights from our global physician community on sustainable practices in healthcare, including operating room innovations and reducing medical waste. Link in comments to our full Press Release and to the full report! 👇 #Sustainability #Healthcare #ESG #GreenHealthcare

G-Med is proud to strengthen our commitment to #sustainability with an updated #ESG policy, focused on reducing waste, conserving resources, and promoting #diversity across the healthcare #ecosystem. Our latest white paper, developed through discussions between our global physician community, explores innovative approaches to sustainability in #healthcare and dives into the debates and discussions our community has been engaging in. Read our full Press Release, and our most recent whitepaper for peer-driven insights on how we can make healthcare greener together! (Links in comments 👇 )

The #hematology diagnostics market is poised for significant growth, but it comes with challenges—especially the high cost of advanced diagnostic equipment, limiting access in developing regions. #Healthcare #marketers need to rethink strategies by positioning affordable alternatives or financing options to appeal to a broader audience. Curious how to navigate these complexities? Read G-Med's latest blog to explore actionable insights for marketing in this evolving market. Link in comments 👇 Merck Bristol Myers Squibb

The Type 2 #Diabetes market is set to grow from $23.4B in 2023 to $42.8B by 2034, driven by innovative treatments like GLP-1 receptor agonists and SGLT-2 inhibitors, alongside digital tools such as CGMs. This shift reflects a preemptive approach, focusing on prevention and early intervention rather than symptom control. Healthcare marketers promoting diabetes solutions need to align with this trend, especially when targeting #HCP audiences. Educating providers on these cutting-edge treatments and prevention strategies will be key to staying ahead in this evolving market. Link to G-Med's latest blog on this in the comment section 👇 #HealthcareMarketing #Innovation #Jardiance #Ozempic #Trulicity Eli Lilly and Company Boehringer Ingelheim Novo Nordisk